Sandoz announces that the US FDA has approved the marketing of its biosimilar Pyzchiva (ustekinumab-ttwe) for all indications of the reference drug Stelara (ustekinumab), with launch scheduled for February 2025.

Stelara is approved to treat adult and pediatric patients with diseases such as plaque psoriasis, active psoriatic arthritis, Crohn's disease and ulcerative colitis.

In addition, the FDA has provisionally determined that Pyzchiva would be interchangeable with the reference drug, as it is currently subject to an unexpired exclusivity period for the first interchangeable biosimilar biologics.

Copyright (c) 2024 CercleFinance.com. All rights reserved.